Exploratory study of biomarkers for therapeutic efficacy and immune-related adverse events of immune checkpoint inhibitors

Exploratory study of biomarkers for therapeutic efficacy and immune-related adverse events of immune checkpoint inhibitors - Biomarkers of immune checkpoint inhibitors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043798

Enrollment

1500

Registered

2021-04-01

Start date

2021-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All cancer types indicated for immune checkpoint inhibitor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cancer patients who are scheduled to receive, or have received, immune checkpoint inhibitors at our hospital or related facilities. 2. 20 years of age or older with the ability to make decisions for themselves.

Exclusion criteria

Exclusion criteria: The patient whom the researcher consider to be inappropriate for the study.

Design outcomes

Primary

Measure	Time frame
Identification of genetic factors associated with immune-related adverse events	—

Secondary

Measure	Time frame
Identification of genetic factors associated with the therapeutic effects of immune checkpoint inhibitors	—

Countries

Japan

Contacts

Public ContactHideaki Miyamoto

Faculty of Life Sciences, Kumamoto University Department of Gastroenterology and Hepatology

hidemyam@kuh.kumamoto-u.ac.jp0963735150

Outcome results